cbdMD, Inc.

YCBD Healthcare Drug Manufacturers Specialty & Generic

cbdMD, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $19.2 million, down 1.50% from fiscal 2024. In the quarter to June 2026, revenue grew 20.6%, EPS grew 47.6% and free cash flow grew 34.8%, each against the same quarter a year earlier.

0.35 0.01 −2.78%
Market cap
$4.0M
P/E
41.2×
Fwd P/E
−3.8×
Dividend yield
—
F-score
6/9
Altman Z
−21.65
Beneish M
−2.51
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
78.82 0.00 0.00 0.00

+8 more quarters

P/S ratio
0.34 0.39 0.64 0.25
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(16.09) (10.70) (14.96) (20.21)
P/B ratio
0.87 0.83 1.35 0.67
EV/Sales
0.35 0.38 0.59 0.26
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(2.98) (2.75) (5.07) (2.94)
Current Ratio
2.50 2.82 2.94 2.05
Net Debt/EBITDA
3.07 6.98 (26.00) 8.93
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
1.27% (12.36%) (141.59%) (300.12%)
Free Cash Flow Yield
(34.86%) (35.26%) (18.11%) (35.06%)
Free Cash Flow per Share
(0.04) (0.07) (0.11) (0.06)
Book value per Share
0.77 0.89 1.00 1.80
Free Cash Flow
(0.46) (0.73) (0.98) (0.24)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates